Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 109-115

  Duwensee, Kristina ^a   Schwaiger, Stefan ^b   Tancevski, Ivan ^a   Eller, Kathrin ^c   van Eck, Miranda ^d   Markt, Patrick ^e   Linder, Tobias ^e   Stanzl, Ursula ^a   Ritsch, Andreas ^a   Patsch, Josef R ^a   Schuster, Daniela ^e   Stuppner, Hermann ^b   Bernhard, David ^f   Eller, Philipp ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d LEIDEN UNIVERSITY   (Netherlands)

^e Institute of Pharmacy Pharmaceutical Chemistry   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cholesterol metabolism; Cholesteryl ester transfer protein; High density lipoproteins

Indexed keywords

5 METHOXYLEOLIGIN [4 (3,4 DIMETHOXYBENZYL) 2 (3,4,5 TRIMETHOXYPHENYL)TETRAHYDROFURAN 3 YL]METHYL 2 METHYLBUT 2 EN OATE; 5,5' DIMETHOXYLEOLIGIN [4 (3,4,5 TRIMETHOXYBENZYL) 2 (3,4,5 TRIMETHOXYPHENYL)TETRAHYDROFURAN 3 YL]METHYL 2 METHYLBUT 2 EN OATE; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LEOLIGIN; LIGNAN; NATURAL PRODUCT; PROBUCOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; EDELWEISS; FLUOROMETER; LEONTOPODIUM ALPINUM; LIPOPROTEIN METABOLISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; PLANT; PLANT ROOT; PLASMA; PRIORITY JOURNAL; RABBIT; SWITZERLAND; TRANSGENIC MOUSE;

ANIMALS; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; LIGNANS; MICE; MICE, TRANSGENIC; MOLECULAR DYNAMICS SIMULATION; RABBITS;

EID: 80055023008     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.023     Document Type: Article

References (29)

1. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
2. Patsch J.R., Prasad S., Gotto A.M., Patsch W. High density lipoprotein 2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 1987, 80:341-347.
3. Tall A.R. Plasma cholesteryl ester transfer protein. J Lipid Res 1993, 34:1255-1274.
4. Inazu A., Brown M.L., Hesler C.B., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990, 323:1234-1238.
5. Brousseau M.E., Schaefer E.J., Wolfe M.L., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.
6. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620-1630.
7. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
8. Cannon C.P., Shah S., Dansky H.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363:2406-2415.
9. Duwensee K., Breitling L.P., Tancevski I., et al. Cholesteryl ester transfer protein in patients with coronary heart disease. Eur J Clin Invest 2010, 40:616-622.
10. Ritsch A., Scharnagl H., Eller P., et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010, 121:366-374.
11. Vasan R.S., Pencina M.J., Robins S.J., et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009, 120:2414-2420.
12. Franceschini G., Sirtori M., Vaccarino V., et al. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 1989, 9:462-469.
13. Yamamoto A., Matsuzawa Y., Yokoyama S., et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986, 57:29H-35H.
14. Quinet E.M., Huerta P., Nancoo D., et al. Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence. J Lipid Res 1993, 34:845-852.
15. Yamashita S., Matsuzawa Y. Where are we with probucol: a new life for an old drug?. Atherosclerosis 2009, 207:16-23.
16. von Eckardstein A. Mulling over the odds of CETP inhibition. Eur Heart J 2010, 31:390-393.
17. Reisinger U., Schwaiger S., Zeller I., et al. Leoligin, the major lignan from Edelweiss, inhibits intimal hyperplasia of venous bypass grafts. Cardiovasc Res 2009, 82:542-549.
18. Schwaiger S., Adams M., Seger C., et al. New constituents of Leontopodium alpinum and their in vitro leukotriene biosynthesis inhibitory activity. Planta Med 2004, 70:978-985.
19. Schuster D. 3D Pharmacophores as tools for activity profiling. Drug Discov Today Technol 2010, 7:205-211.
20. Tancevski I., Frank S., Massoner P., et al. Increased plasma levels of LDL cholesterol in rabbits after adenoviral over expression of human scavenger receptor class B type I. J Mol Med 2005, 83:927-932.
21. Ritsch A., Auer B., Foger B., et al. Polyclonal antibody-based immunoradiometric assay for quantification of cholesteryl ester transfer protein. J Lipid Res 1993, 34:673-679.
22. Borggreve S.E., Hillege H.L., Wolffenbuttel B.H., et al. The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J Clin Endocrinol Metab 2005, 90:4198-4204.
23. Hoekstra M., Ye D., Hildebrand R.B., Zhao Y., et al. Scavenger receptor class B type I-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production. J Lipid Res 2009, 50:1039-1046.
24. Eller P., Eller K., Wolf A.M., Reinstadler S.J., et al. Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. Kidney Int 2010, 77:428-435.
25. Qiu X., Mistry A., Ammirati M.J., et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol 2007, 14:106-113.
26. Sirtori C.R., Mombelli G. Cholesteryl ester transfer protein antagonism by drugs - a poor choice. Clin Chem 2010, 56:1550-1553.
27. Quintao E.C., Cazita P.M. Lipid transfer proteins: past, present and perspectives. Atherosclerosis 2010, 209:1-9.
28. Heinecke J. HDL and cardiovascular-disease risk - time for a new approach?. N Engl J Med 2011, 364:170-171.
29. Sawayama Y., Shimizu C., Maeda N., et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002, 39:610-616.